| Health / Medical Topics |
VHL2 (Y12M) Peptide
A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL2 (Y12M) peptide is a point mutation variant (from tyrosine to methionine at amino acid position 12) of the VHL protein. Vaccination with this peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein. (NCI Thesaurus)
YOU MAY ALSO LIKE
A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL16 peptide, also known as S111I,…
A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL14 peptide is a point…
A peptide vaccine consisting of amino acids 116 through 128 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a frameshift…
A peptide vaccine consisting of amino acids 65 through 76 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a glycine…
Human VHL wild-type allele is located within 3p26-p25 and is approximately 10 kb in length. This allele, which encodes von Hippel-Lindau disease…
A rare inherited disorder in which blood vessels grow abnormally in the eyes, brain, spinal cord, adrenal glands, or other parts of…
